|
Description
M2 PRESSWIRE-15 January 2008-BUYINS.NET: ABPI, CENT, COIN, CPLP, FLIP, RGRP Have Also Been Added To Naked Short List Today(C)1994-2008 M2 COMMUNICATIONS LTD
RDATE:15012008
BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Accentia Biopharmaceuticals Inc. (NASDAQ: ABPI), Central Garden & Pet Company (NASDAQ: CENT), Converted Organics Inc. (NASDAQ: COIN), Capital Product Partners L.P. Common Units (NASDAQ: CPLP), FTS Group Inc. (OTCBB: FLIP), ROO Group Inc. New (OTCBB: RGRP). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net.
Accentia Biopharmaceuticals Inc. (NASDAQ: ABPI) a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis; BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma; and Revimmune for the treatment of multiple sclerosis, an autoimmune disease that affects the central nervous system, and various autoimmune diseases, including systemic lupus, myasthenia gravis, and aplastic anemia. This segment also provides various consulting services relating to biopharmaceutical product development; and engages in the production of custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its products comprise Respi-TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; SinuTest, a test used in connection with the diagnosis of chronic sinusitis; and... |
More articles from M2 Presswire
A Look into Advanced Analogic Technologies, Inc., January 15, 2008
AngloGold Ashanti Agrees to Acquire 100% of Golden Cycle Gold Corporat..., January 15, 2008
A Look into CardioDynamics., January 15, 2008
Early Market Standouts List TheSUBWAYs New Small Cap Investor Forum Sp..., January 15, 2008
Strong schools and colleges urged to share their formula for success t..., January 15, 2008
Looking for additional articles?
Click here
to search our database of over 3 million articles.
|
